# Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

> **NCT00544167** · NA · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 45 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00544167
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-01
- **Final completion:** 2011-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2013-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544167, "Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00544167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*